Systematic surveillance of SARS-CoV-2 reveals dynamics of variant mutagenesis and transmission in a large urban population

Marie-Ming Aynaud, Lauren Caldwell, Khalid N. Al-Zahrani, Seda Barutcu, Kin Chan, Andreea Obersterescu, Abiodun A. Ogunjimi, Min Jin, Kathleen-Rose Zakoor, Shyam Patel, Ron Padilla, Mark Jen, Princess Mae Veniegas, Nursrin Dewsi, Filiam Yonathan, Lucy Zhang, Amelia Ayson-Fortunato, Analiza Aquino, Paul Krzyzanowski, Jared Simpson, John Bartlett, Ilinca Lungu, Bradley G. Wouters, James M. Rini, Michael Gekas, Susan Poutanen, Laurence Pelletier, Tony Mazzulli, and Jeffrey L. Wrana

Supplementary informations:

Supplementary Fig. 1 to 14 Supplementary Table 1 to 7



Assign variants of concern and/or mutations to samples based on quantified variant reads (See panel b for mutation-to-variant calling)



Supplementary Fig. 1 Summary of analysis pipeline. a. Each step of the pipeline is detailed. **b.** Schematic of the VOCs and C19-SPAR-Seq V1 and V2 coverage on *S-Rbm* and *S-Pbs*.

Approx Timeline for one 384 well plate



Supplementary Fig. 2

Supplementary Fig. 2 Timing of the semi-automated C19-SPAR-Seq.



Supplementary Fig. 3

Supplementary Fig. 3 C19 SPAR-Seq V2 validation. a. Schematic representation of the V1 and V2 primer pairs of the SARS-CoV-2 S-*Rbm* region (upper panel). The efficiency of *S-Rbm*-V2 set of primers. Standard curve of Ct values (Y-axis) and log₁₀(Concentration) (X-axis) of 5 limited dilutions of HEK293T/Twist RNA. Each condition was tested in duplicate. Means are plotted for each point. After linear regression, the percent efficiency and the Spearman correlation are calculated for each

pair of primers (lower panel). **b.** Comparison of fragment analyzer profile of the V1 Multiplex (left panel) and V2 multiplex set of primers (right panel) after 1X/1X SPRI bead purification. Fragment separation (DNA gel) and a blow-up view of the product abundance (electropherogram) are shown. Expected library amplicons (red stars) and non-specific amplicons (black stars) are annotated. **c.** Correlation plot of the total raw read counts of *S-Rbm* using both V1 and V2 primer sets for four clinical runs of the C19-SPAR-Seq pipeline is shown.



Supplementary Fig. 4

Supplementary Fig. 4 Correlation plot of the total raw read counts of *RdRP*, *S-Pbs* and *ACTB* using both V1 and V2 primer sets for four clinical runs of C19-SPAR-Seq.



Supplementary Fig. 5

Supplementary Fig. 5 Quantification of C19-SPAR-Seq technical

contamination. a. Schematic of the 384 Well-BC-*S-Rbm* pair of primer designs. **b.** Fragment analyzer profile V2 Well-BC-multiplex set of primers (right panel) after 1X/1X SPRI bead purification. Fragment separation (DNA gel) and a blow-up view of the product abundance (electropherogram) are shown. Expected library amplicons (red stars) and non-specific amplicons (black stars) are annotated. **c.** Boxplot of contamination for the percentage of BCs in the correct well for the six clinical runs. **d**. Boxplot of cross contamination for the percentage of correctly paired BCs in the incorrect well for the six clinical runs.



Supplementary Fig. 6 Total reads for each Barcoded run. Red dots indicate low

quality samples.



Supplementary Fig. 7 Schematic of the percentage of correctly paired well-

barcoded in the correct well in 384 well plates. Wells highlighted in red are samples

with a low total read count (see Supplementary Fig. 6)



Supplementary Fig. 8 Heatmap of all the unique VOC subvariants over time.



Supplementary Fig. 9

Supplementary Fig. 9 VOCs and VOC subvariant distribution. a. Total cases of each VOC. **b.** Total number of different unique mutational profiles per VOC. **c.** Proportion of cases of VOCs with subvariants (shaded areas). **d.** For each amplicon, the number of amino acid positions in which we detected a variant in the different VOCs.



Supplementary Fig. 10 VOC subvariants. a. VOC subvariant of *S-Pbs* insertion and deletion. **b.** The percentage of the top reads out of the total read counts per amplicon, per sample, are plotted for each of the VOCs and VOC subvariants.



Supplementary Fig. 11 Affinity Assay of WT, Alpha, Alpha + F490L, Beta, Delta and

Omicron



Supplementary Fig. 12 Filtering and threshold development for putative quasispecies analysis, and pQS results for *S-Pbs* sequences. **a.** Counts per sample of *S-Rbm* reads with the cutoff line shown at 32,000 counts (left panel) and analysis to determine the finalized threshold for *S-Rbm* reads (right panel). **b.** Analysis to determine the finalized threshold for *S-Pbs* reads. **c.** Count of *S-Pbs* pQS per VOC as percent of total detected pQS. **d.** Alignment of *S-Pbs* pQS sequences.



Supplementary Fig. 13

Supplementary Fig. 13 Total percent of reads per sample that is made up of pQS sequences.



а

Supplementary Fig. 14 Summary of S-Rbm and S-Pbs pQS. a. *S-Rbm* pQS: nucleotide mutation (left panel) and amino acid mutation (right panel). **b.** *S-Pbs* pQS: nucleotide mutation (left panel) and amino acid mutation (right panel).

sequence	Name	Version
acactctttccctacacgacgctcttccgatctATCAGGCCGGTAGCACACCT	013-S-RBD-For	V1
gtgactggagttcagacgtgtgctcttccgatctACTCTGTATGGTTGGTAACCAACAC	013-S-RBD-Rev	V1
acactctttccctacacgacgctcttccgatctTATGCGCTAGTTATCAGACTCAGAC	014-S-PBS-For	V1/V2
gtgactggagttcagacgtgtgctcttccgatctGTAAGCAACTGAATTTTCTGCACCA	014-S-PBS-Rev	V1/V2
acactctttccctacacgacgctcttccgatctGATGCCACAACTGCTTATGC	023-RdRP-For	V1/V2
gtgactggagttcagacgtgtgctcttccgatctTTGCGGACATACTTATCGGC	023-RdRP-Rev	V1/V2
acactctttccctacacgacgctcttccgatctTCACCATTGGCAATGAGCGGTTC	019-ACTB/G-For	V1/V2
gtgactggagttcagacgtgtgctcttccgatctCCACGTCACACTTCATGATGGAG	019-ACTB/G-Rev	V1/V2
acactctttccctacacgacgctcttccgatctACCTTTTGAGAGAGATATTTCAACTGA	S-RBD-V2-For	V2
gtgactggagttcagacgtgtgctcttccgatctACTACTACTCTGTATGGTTGGT	S-RBD-V2-Rev	V2

Supplementary Table 1. List of SARS-CoV-2 and human primers

Description	Number Failed in Pilot Cohort (from 1,218 sample	Number Failed in Total Cohort (from 73,510 samples)
QC Fail	20	7,345
QC Pass	1,198	66,165

Supplementary Table 2. Summary of samples which failed quality control cutoffs.

Sequence name	Lineage	Conflict	Ambiguity score	Scorpio call	Scorpio suppor	Scorpio conflict	Note	pangolin version	pangolin-data version	Variant type SPAR-Seq detected
W42207758	B.1.2	0					Assigned from designation hash.	4.1.3	v1.15.1	C179 (Asn -> Lys)
W41900420	B.1.2	0					Usher placements: B.1.2(1/1)	4.1.3	v1.15.1	C484 (Glu -> Lys)
W41809599	B.1.2	0	ŀ				Assigned from designation hash.	4.1.3	v1.15.1	C179 (Asn -> Lys)
W41808799	B.1.36.18	0					Assigned from designation hash.	4.1.3	v1.15.1	High
W41805394	AL.1	0	ŀ				Assigned from designation hash.	4.1.3	v1.15.1	High
W41809402	B.1.469	0					Usher placements: B.1.469(1/1)	4.1.3	v1.15.1	C681(Pro -> His)
W41809395	B.1.469	0	ŀ				Assigned from designation hash.	4.1.3	v1.15.1	C681(Pro -> His)
W41809377	B.1.243	0					Assigned from designation hash.	4.1.3	v1.15.1	C681(Pro -> His)
W41907070	P.2	0		Zeta (P.2-like	0.86	0.14	Assigned from designation hash.	4.1.3	v1.15.1	C484 (Glu -> Lys)
W41907062	P.2	0	ŀ	Zeta (P.2-like	0.86	0.14	Assigned from designation hash.	4.1.3	v1.15.1	C484 (Glu -> Lys)
W41906025	B.1.2	0					Usher placements: B.1.2(1/1)	4.1.3	v1.15.1	C179 (Asn -> Lys)
W42002970	B.1.36.18	0					Usher placements: B.1.36.18(1/1)	4.1.3	v1.15.1	Medium
W42005505	B.1.2	0					Assigned from designation hash.	4.1.3	v1.15.1	C179 (Asn -> Lys)
W42004805	B.1.36.38	0	ŀ				Assigned from designation hash.	4.1.3	v1.15.1	Medium
W42005597	AM.4	0					Assigned from designation hash.	4.1.3	v1.15.1	C484 (Glu -> Lys)
W42204655	B.1.2	0					Assigned from designation hash.	4.1.3	v1.15.1	C179 (Asn -> Lys)
W42104455	B.1.243	0	ŀ				Assigned from designation hash.	4.1.3	v1.15.1	C681(Pro -> His)
W42205151	P.2	0		Zeta (P.2-like	0.86	0.14	Assigned from designation hash.	4.1.3	v1.15.1	C484 (Glu -> Lys)
W42103083	B.1.36.18	0	ŀ				Usher placements: B.1.36.18(1/1)	4.1.3	v1.15.1	Low
W42203027	B.1.2	0					Assigned from designation hash.	4.1.3	v1.15.1	C179 (Asn -> Lys)
W42207759	B.1.2	0					Assigned from designation hash.	4.1.3	v1.15.1	C179 (Asn -> Lys)

Supplementary Table 3. Pangolin output of whole genome sequencing results.

Name	Sequence
S_Rbd_V2_For_well-BC_1	acactctttccctacacgacgctcttccgatctACGTAACCTTTTGAGAGAGATATTTCAACTGA
S_Rbd_V2_For_well-BC_2	acactctttccctacacgacgctcttccgatctCGTACACCTTTTGAGAGAGATATTTCAACTGA
S_Rbd_V2_For_well-BC_3	acactctttccctacacgacgctcttccgatctGTACCACCTTTTGAGAGAGATATTTCAACTGA
S_Rbd_V2_For_well-BC_4	acactctttccctacacgacgctcttccgatctTACGGACCTTTTGAGAGAGATATTTCAACTGA
S_Rbd_V2_For_well-BC_5	acactctttccctacacgacgctcttccgatctAGGACACCTTTTGAGAGAGATATTTCAACTGA
S_Rbd_V2_For_well-BC_6	acactctttccctacacgacgctcttccgatctCTTCGACCTTTTGAGAGAGATATTTCAACTGA
S_Rbd_V2_For_well-BC_7	acactctttccctacacgacgctcttccgatctGAAGTACCTTTTGAGAGAGATATTTCAACTGA
S_Rbd_V2_For_well-BC_8	acactctttccctacacgacgctcttccgatctTCCTAACCTTTTGAGAGAGATATTTCAACTGA
S_Rbd_V2_For_well-BC_9	acactctttccctacacgacgctcttccgatctAGTGCACCTTTTGAGAGAGATATTTCAACTGA
S_Rbd_V2_For_well-BC_10	acactctttccctacacgacgctcttccgatctCTATGACCTTTTGAGAGAGATATTTCAACTGA
S_Rbd_V2_For_well-BC_11	acactctttccctacacgacgctcttccgatctGATACACCTTTTGAGAGAGATATTTCAACTGA
S_Rbd_V2_For_well-BC_12	acactctttccctacacgacgctcttccgatctTCACGACCTTTTGAGAGAGATATTTCAACTGA
S_Rbd_V2_For_well-BC_13	acactctttccctacacgacgctcttccgatctAGCGTACCTTTTGAGAGAGATATTTCAACTGA
S_Rbd_V2_For_well-BC_14	acactctttccctacacgacgctcttccgatctCTGACACCTTTTGAGAGAGATATTTCAACTGA
S_Rbd_V2_For_well-BC_15	acactctttccctacacgacgctcttccgatctGATCGACCTTTTGAGAGAGATATTTCAACTGA
S_Rbd_V2_For_well-BC_16	acactctttccctacacgacgctcttccgatctTCGGGAACCTTTTGAGAGAGATATTTCAACTGA
S_Rbd_V2_Rev_well-BC_1	gtgactggagttcagacgtgtgctcttccgatctGCTACACTACTACTCTGTATGGTTGGT
S_Rbd_V2_Rev_well-BC_2	gtgactggagttcagacgtgtgctcttccgatctTGACGACTACTACTCTGTATGGTTGGT
S_Rbd_V2_Rev_well-BC_3	gtgactggagttcagacgtgtgctcttccgatctATCGTACTACTACTCTGTATGGTTGGT
S_Rbd_V2_Rev_well-BC_4	gtgactggagttcagacgtgtgctcttccgatctCAGTAACTACTACTCTGTATGGTTGGT
S_Rbd_V2_Rev_well-BC_5	gtgactggagttcagacgtgtgctcttccgatctGTCACACTACTACTCTGTATGGTTGGT
S_Rbd_V2_Rev_well-BC_6	gtgactggagttcagacgtgtgctcttccgatctTAGCGACTACTACTCTGTATGGTTGGT
S_Rbd_V2_Rev_well-BC_7	gtgactggagttcagacgtgtgctcttccgatctACTGTACTACTACTCTGTATGGTTGGT
S_Rbd_V2_Rev_well-BC_8	gtgactggagttcagacgtgtgctcttccgatctCGATAACTACTACTCTGTATGGTTGGT
S_Rbd_V2_Rev_well-BC_9	gtgactggagttcagacgtgtgctcttccgatctGTTGCACTACTACTCTGTATGGTTGGT
S_Rbd_V2_Rev_well-BC_10	gtgactggagttcagacgtgtgctcttccgatctTAATGACTACTACTCTGTATGGTTGGT
S_Rbd_V2_Rev_well-BC_11	gtgactggagttcagacgtgtgctcttccgatctACGATACTACTACTCTGTATGGTTGGT
S_Rbd_V2_Rev_well-BC_12	gtgactggagttcagacgtgtgctcttccgatctCGTCAACTACTACTCTGTATGGTTGGT
S_Rbd_V2_Rev_well-BC_13	gtgactggagttcagacgtgtgctcttccgatctGTAGCACTACTACTCTGTATGGTTGGT
S_Rbd_V2_Rev_well-BC_14	gtgactggagttcagacgtgtgctcttccgatctTACTGACTACTACTCTGTATGGTTGGT
S_Rbd_V2_Rev_well-BC_15	gtgactggagttcagacgtgtgctcttccgatctAGTACACTACTACTCTGTATGGTTGGT
S_Rbd_V2_Rev_well-BC_16	gtgactggagttcagacgtgtgctcttccgatctCTACGACTACTACTCTGTATGGTTGGT
S_Rbd_V2_Rev_well-BC_17	gtgactggagttcagacgtgtgctcttccgatctGACGTACTACTACTCTGTATGGTTGGT
S_Rbd_V2_Rev_well-BC_18	gtgactggagttcagacgtgtgctcttccgatctTCGTAACTACTACTCTGTATGGTTGGT
S_Rbd_V2_Rev_well-BC_19	gtgactggagttcagacgtgtgctcttccgatctAGCACACTACTACTCTGTATGGTTGGT
S_Rbd_V2_Rev_well-BC_20	gtgactggagttcagacgtgtgctcttccgatctCTGCGACTACTACTCTGTATGGTTGGT
S_Rbd_V2_Rev_well-BC_21	gtgactggagttcagacgtgtgctcttccgatctGATTGACTACTACTCTGTATGGTTGGT
S_Rbd_V2_Rev_well-BC_22	gtgactggagttcagacgtgtgctcttccgatctTCAATACTACTACTCTGTATGGTTGGT
S_Rbd_V2_Rev_well-BC_23	gtgactggagttcagacgtgtgctcttccgatctAGCCAACTACTACTCTGTATGGTTGGT
S_Rbd_V2_Rev_well-BC_24	gtgactggagttcagacgtgtgctcttccgatctCTGGCACTACTACTCTGTATGGTTGGT

Supplementary Table 4: S-Rbm-well-BC primer list.

Variant of Concern	Woldwide Emergence (Locatio	Worldwide Emergence (Date)	First Case Detected by C19-SPAR-Seq
Alpha (B1.1.7)	United Kingdom	September 2020	December 2020
Beta (B.1.351)	South Africa	May 2020	December 2020
Gamma (P.1)	Brazil	November 2020	January 2021
Delta (B.1.617.2)	India	October 2020	June 2021
Omicron (B.1.1.529)	South Africa	November 2021	November 2021
Omicron (BA.2)	South Africa	November 2021	December 2021
Omicron (BA.3)	South Africa	November 2021	December 2021
Omicron (BA.4)	South Africa	January 2022	May 2022
Omicron (BA.5)	South Africa	February 2022	May 2022
Omicron (XBB)	India	August 2022	November 2022
Omicron (XBB. 1.5)	United States	October 2022	December 2022

Supplementary Table 5. Date of first detection of global variants of concern within

Toronto.

Date	# Fig 3	status	Milestone	Web link		
January 23th, 2021	1	Closing	Stay-at-home order for all Ontario, eg: Province under a provincewide Stay-at-Home order, requiring everyone to remain at home except for essential purposes, such as going to the grocery store or pharmacy, accessing health care services (including getting vaccinated), for outdoor exercisewith your household in your home community, or for work that cannot be done remotely	https://news.ontario.ca/en/release/60261/ontario-extending-stay- home-order-across-most-of-the-province-to-save-lives		
February 8th, 2021	2	Opening	Return to the classroom in-person learning for regions other than Peel, Toronto, York	https://toronto.citynews.ca/2021/03/11/timeline-a-year-of-pandemic- life/		
February 16th, 2021	3	Opening	Stay-at-home order lifted; return to classroom in-person learning for Peel, Toronto, York	https://news.ontario.ca/en/release/60228/enhanced-safety-measures- in-place-as-in-person-learning-resumes-across-ontario		
February 22nd, 2021	4	Closing	Back to stay-at-home order	https://news.ontario.ca/en/release/60261/ontario-extending-stay-at- home-order-across-most-of-the-province-to-save-lives		
March 8th, 2021	5	Opening	Stay-at-home order lifted	https://news.ontario.ca/en/release/60261/ontario-extending-stay-at- home-order-across-most-of-the-province-to-save-lives		
April 3rd, 2021	6	Closing	Return to stay at home	https://toronto.citynews.ca/2021/03/08/covid-19-grey-zone-toronto- peel/		
April 19 2021	7	Closing	Return to remote learning	https://news.ontario.ca/en/release/61106/ontario-moves-schools-to- remote-learning-following-spring-break		
June 1st, 2021	8		Start of daily SPAR-seq testing	https://globalnews.ca/news/7743332/ontario-covid-stay-at-home- order/		
June 2 2021	9	Closing	Ontario continues remote learning until end of school year	https://news.ontario.ca/en/release/1000251/remote-learning-to- continue-across-ontario-for-the-remainder-of-school-year		
June 11th, 2021	10	Opening	Reopening phase 1 including loosening of restrictions to outdoor areas/gatherings ("Step 1 of the Roadmap To Reopen plan") (https://news.ontario.ca/en/backgrounder/1000159/roadmap-to-reopen)	https://news.ontario.ca/en/release/1000279/ontario-to-move-to-step- one-of-roadmap-to-reopen-on-june-11		
June 30th, 2021	11	Opening	Reopening phase 2 including loosening of restrictions in some indoor and further outdoor areas ("Step 2 of the Roadmap To Reopen plan") (https://news.ontario.ca/en/backgrounder/1000159/roadmap-to-reopen)	https://news.ontario.ca/en/release/1000399/ontario-moving-to-step- two-of-roadmap-to-reopen-on-june-30		
July 16 2021	12	Opening	Reopening phase 3 including futher loosing of resrictions in indoor areas ("Step 3 of the Roadmap To Reopen plan") (https://news.ontario.ca/en/backgrounder/1000159/roadmap-to-reopen)	https://news.ontario.ca/en/release/1000501/ontario-moving-to-step- three-of-roadmap-to-reopen-on-july-16		
Sep 8 2021	13	Opening	Return to in person learning	https://www.ontario.ca/document/covid-19-health-safety-and- operational-guidance-schools-2021-2022		
Oct 25 2021	14	Opening	Ontario will lift capacity limits, including physical distancing requirements, in the vast majority of settings where proof	https://news.ontario.ca/en/release/1001027/ontario-releases-plan-to-		
November 30th, 2021	15	Closing	Border measures: Entry prohibitions for travellers coming from 13 African countries as response to first reported	https://www.ctvnews.ca/health/coronavirus/canada-bans-travellers-		
Dec 19 2021	16	Closing	Ontario returns to restrictions on indoor settings as response to increasing cases	https://toronto.ctvnews.ca/ontario-slashing-gathering-sizes-reducing-		
December 31th, 2021	17		End of systematic COVID19 screening for the public	https://news.ontario.ca/en/backgrounder/1001387/updated-eligibility-		
January 5 2022	18	Closing	Return to step 2 of "Roadmap to Reopen Plan", schools closed	https://news.ontario.ca/en/release/1001394/ontario-temporarily-		

Supplementary Table 6. List of dates and descriptions of non-pharmaceutical interventions and other relevant events in the GTA from January 2021 to January 2022.

						S-Pbs Output	
		Samples	S-Rbm Output		Samples	Sequences	S-Pbs Unique
	Input Samples	producing an S-	Sequences (total	S-Rbm Unique Output	producing an S-	(total count, not	Output
Variant	(total 1110)	Rbm sequence	count, not unique)	Sequences	Pbs sequence	unique)	Sequences
WT	301	145 (48.17%)	225	13	1 (0.33%)	1	1
Alpha	75	38 (50.67%)	63	5	4 (5.33%)	4	1
Delta	193	12 (6.23%)	15	6	6 (3.11%)	7	4
Omicron B.1.1.529	541	33 (6.1%)	38	5	10 (1.85%)	10	2

Supplementary Table 7. Summary of samples from different VOCs used for pQS

analysis and the sequences outputted by the analysis.